Yasuyuki Kawagoe Selected Research

Trypsin

10/2017

Antithrombin improves the maternal and neonatal outcomes but not the angiogenic factors in extremely growth-restricted fetuses at <28 weeks of gestation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yasuyuki Kawagoe Research Topics

Disease

1	Carcinoma (Carcinomatosis) 04/2021
1	Neoplasms (Cancer) 04/2021
1	Venous Thromboembolism 04/2021
1	Chorioamnionitis 10/2020
1	Fetal Growth Retardation (Intrauterine Growth Retardation) 10/2020
1	Meningeal Carcinomatosis 01/2018
1	Neoplasm Metastasis (Metastasis) 01/2018
1	Ovarian Neoplasms (Ovarian Cancer) 01/2018
1	Pre-Eclampsia (Preeclampsia) 10/2017
1	Hemolysis 10/2017
1	Sarcoma (Soft Tissue Sarcoma) 10/2017
1	HELLP Syndrome 10/2017
1	Premature Obstetric Labor (Premature Labor) 01/2011

Drug/Important Bio-Agent (IBA)

2	Tocolytic Agents (Tocolytics)IBA 10/2020 - 01/2011
1	Thromboplastin (Tissue Factor)IBA 04/2021
1	P-SelectinIBA 04/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2020
1	GadoliniumIBA 01/2018
1	EnzymesIBA 10/2017
1	TrypsinIBA 10/2017
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2017
1	Magnesium Sulfate (Sulfate, Magnesium)FDA LinkGeneric 01/2011

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2018
1	Radiotherapy 01/2018